Protagonist Therapeutics has gained 149.29% over the past 52 weeks and recently traded at $125.17, with a 50-day moving average of $105.19 and a Weighted Alpha of +121.94. The stock holds a 100% Buy technical opinion from Barchart and has a Trend Seeker Buy signal intact, while Wall Street analysts give it 12 Strong Buy and 2 Hold ratings with price targets between $100 and $137. However, Value Line rates the stock Average, citing low price stability and low earnings predictability, and short interest stands at 12.02% of the float with 11.59 days to cover. Earnings are estimated to increase 303.58% this year but decrease 116.41% next year, and Morningstar considers the stock 6% overvalued with a fair value of $115. The author remains cautious due to high valuation, low growth, and speculative profile, choosing to invest elsewhere despite the bullish momentum.
Protagonist Therapeutics IncStock surged 150% and has strong analyst ratings, but high short interest, low stability, and mixed valuation signals create uncertainty.